A STUDY OF ASSOCIATION BETWEEN RECEPTOR OF TYROSINE KINASE ORPHAN LIKE RECEPTOR (ROR1) AND CHRONIC LYMPHOCYTIC LEUKIMIA (CLL) IN EGYPTIAN PATIENTS.
Elhadidy, A., Ghallab, O., Eldabah, N., Farawila, M. (2024). A STUDY OF ASSOCIATION BETWEEN RECEPTOR OF TYROSINE KINASE ORPHAN LIKE RECEPTOR (ROR1) AND CHRONIC LYMPHOCYTIC LEUKIMIA (CLL) IN EGYPTIAN PATIENTS.. EKB Journal Management System, 6(3), 44-45. doi: 10.21608/alexpo.2024.312076.1918
Abeer Shawky Elhadidy; Omar Mohamed Ghallab; Nermeen Ahmed Mohamed Eldabah; Mennatallah Hesham Farawila. "A STUDY OF ASSOCIATION BETWEEN RECEPTOR OF TYROSINE KINASE ORPHAN LIKE RECEPTOR (ROR1) AND CHRONIC LYMPHOCYTIC LEUKIMIA (CLL) IN EGYPTIAN PATIENTS.". EKB Journal Management System, 6, 3, 2024, 44-45. doi: 10.21608/alexpo.2024.312076.1918
Elhadidy, A., Ghallab, O., Eldabah, N., Farawila, M. (2024). 'A STUDY OF ASSOCIATION BETWEEN RECEPTOR OF TYROSINE KINASE ORPHAN LIKE RECEPTOR (ROR1) AND CHRONIC LYMPHOCYTIC LEUKIMIA (CLL) IN EGYPTIAN PATIENTS.', EKB Journal Management System, 6(3), pp. 44-45. doi: 10.21608/alexpo.2024.312076.1918
Elhadidy, A., Ghallab, O., Eldabah, N., Farawila, M. A STUDY OF ASSOCIATION BETWEEN RECEPTOR OF TYROSINE KINASE ORPHAN LIKE RECEPTOR (ROR1) AND CHRONIC LYMPHOCYTIC LEUKIMIA (CLL) IN EGYPTIAN PATIENTS.. EKB Journal Management System, 2024; 6(3): 44-45. doi: 10.21608/alexpo.2024.312076.1918

A STUDY OF ASSOCIATION BETWEEN RECEPTOR OF TYROSINE KINASE ORPHAN LIKE RECEPTOR (ROR1) AND CHRONIC LYMPHOCYTIC LEUKIMIA (CLL) IN EGYPTIAN PATIENTS.

ALEXMED ePosters
Article 1, Volume 6, Issue 3, July 2024, Page 44-45  XML
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2024.312076.1918
View on SCiNiTO View on SCiNiTO
Authors
Abeer Shawky Elhadidy1; Omar Mohamed Ghallab2; Nermeen Ahmed Mohamed Eldabah1; Mennatallah Hesham Farawila email 1
1Department of Clinical and Chemical Pathology, Faculty of Medicine, Alexandria University
2Department of Internal Medicine – Hematology Unit, Faculty of Medicine, Alexandria University
Abstract
Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia worldwide as in the Egyptian population. In Egypt, it accounts for 3.08 % of lymphoid malignancies and 0.5 % of all cancers.CLL diagnosis requires the existence of at least 5×109 /L circulating mature B-lymphocytes in the peripheral blood for 3 months. The immunophenotype of typical lymphocytes in case of CLL includes the co-expression of weak monotypic surface immunoglobulin, CD5, CD19, CD23 and weak or absent CD79B, CD22 and FMC7. Identification and targeting antigens that are exclusively overexpressed in malignant but not normal cells are crucial for the success of cancer management. In the previous years the application of tumor-associated antigens (TAAs) and tumor-specific antigens (TSAs) as therapeutic, diagnostic and screening targets for cancers become more promising. Theses antigens have a vital role in the growth and survival of malignant cells. ROR-1 is one of the promising TAA in CLL.

AIM OF THE WORK:
The aim of our study
To assess the role of ROR 1in diagnosis of CLL and in minimal residual disease (MRD) of CLL.
Keywords
Chronic lymphocytic leukemia (CLL); ROR1; MRD
Supplementary Files
Statistics
Article View: 85